What Will Happen to Coherus Biosciences Inc Next? The Stock Just Had Huge Bullish Options Activity

 What Will Happen to Coherus Biosciences Inc Next? The Stock Just Had Huge Bullish Options Activity

In today’s session Coherus Biosciences Inc (CHRS) registered an unusually high (444) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious CHRS increase. With 444 contracts traded and 1894 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: CHRS161118C00030000 closed last at: $0.75 or 54.5% down. About 169,755 shares traded hands. Coherus Biosciences Inc (NASDAQ:CHRS) has risen 7.24% since April 7, 2016 and is uptrending. It has outperformed by 2.46% the S&P500.

Analysts await Coherus Biosciences Inc (NASDAQ:CHRS) to report earnings on November, 14. They expect $-1.71 earnings per share, up 8.06% or $0.15 from last year’s $-1.86 per share. After $-1.72 actual earnings per share reported by Coherus Biosciences Inc for the previous quarter, Wall Street now forecasts -0.58% EPS growth.

Coherus Biosciences Inc (NASDAQ:CHRS) Ratings Coverage

Out of 6 analysts covering Coherus Biosciences (NASDAQ:CHRS), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. $46 is the highest target while $36 is the lowest. The $41.25 average target is 56.55% above today’s ($26.35) stock price. Coherus Biosciences has been the topic of 6 analyst reports since September 3, 2015 according to StockzIntelligence Inc. As per Wednesday, October 19, the company rating was initiated by Robert W. Baird. Citigroup initiated the stock with “Buy” rating in Wednesday, July 27 report. The firm earned “Overweight” rating on Monday, November 23 by Barclays Capital. The firm earned “Hold” rating on Thursday, September 3 by Zacks. As per Wednesday, September 7, the company rating was initiated by Maxim Group. Credit Suisse initiated the shares of CHRS in a report on Wednesday, January 20 with “Outperform” rating.

According to Zacks Investment Research, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.”

Insitutional Activity: The institutional sentiment increased to 3.32 in 2016 Q2. Its up 1.99, from 1.33 in 2016Q1. The ratio improved, as 10 funds sold all Coherus Biosciences Inc shares owned while 9 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 49.39 million shares or 180.37% more from 17.62 million shares in 2016Q1.
Lombard Odier Asset Management (Switzerland) accumulated 109,664 shares or 0.25% of the stock. Blackrock Advisors Lc has 18,243 shares for 0% of their US portfolio. Point72 Asset Mgmt L P accumulated 0% or 37,500 shares. Jacobs Levy Equity Mngmt Incorporated has 12,800 shares for 0% of their US portfolio. Wfg Ltd Partnership last reported 1,800 shares in the company. Strs Ohio last reported 0% of its portfolio in the stock. Geode Capital Mgmt Ltd Company last reported 205,465 shares in the company. Blackrock Institutional Tru Na has 0% invested in the company for 474,993 shares. Bnp Paribas Arbitrage reported 1,144 shares or 0% of all its holdings. Millennium Mgmt Ltd Liability Company accumulated 0.02% or 400,940 shares. Spark Mngmt last reported 185,400 shares in the company. Iguana Healthcare Mngmt Limited Liability Company has 75,000 shares for 0.52% of their US portfolio. Allianz Asset Mngmt Ag accumulated 0% or 46,259 shares. Blackrock Inc accumulated 0% or 7,659 shares. Commercial Bank Of America Corp De accumulated 4,897 shares or 0% of the stock.

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The company has a market cap of $1.08 billion. The Firm is focused on the global biosimilar market. It currently has negative earnings. The Firm operates through developing and commercializing biosimilar products segment.

CHRS Company Profile

Coherus BioSciences, Inc., incorporated on September 29, 2010, is a late-stage clinical biologics platform company. The Firm is focused on the global biosimilar market. The Firm operates through developing and commercializing biosimilar products segment. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

More notable recent Coherus Biosciences Inc (NASDAQ:CHRS) news were published by: Fool.com which released: “Why Coherus BioSciences, Inc. Is Dropping Today” on November 07, 2016, also Globenewswire.com with their article: “Coherus BioSciences to Report Third Quarter 2016 Financial Results on November 9th” published on November 01, 2016, Globenewswire.com published: “Coherus BioSciences Announces FDA Acceptance of 351(k) Biologics License …” on October 06, 2016. More interesting news about Coherus Biosciences Inc (NASDAQ:CHRS) were released by: Globenewswire.com and their article: “Coherus BioSciences Appoints Patrick O’Brien as Senior Vice President …” published on May 16, 2016 as well as Fool.com‘s news article titled: “Coherus Biosciences and Baxalta Take Aim at Amgen and Pfizer” with publication date: January 12, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment